File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Oral iloprost as a treatment for Raynaud's syndrome: A double blind multicentre placebo controlled study

TitleOral iloprost as a treatment for Raynaud's syndrome: A double blind multicentre placebo controlled study
Authors
Issue Date1995
PublisherB M J Publishing Group. The Journal's web site is located at http://ard.bmjjournals.com/
Citation
Annals Of The Rheumatic Diseases, 1995, v. 54 n. 3, p. 197-200 How to Cite?
AbstractObjective - To compare the efficacy, tolerance and safety of 50-150 μg orally administered iloprost given twice a day versus placebo in patients with Raynaud's syndrome. Methods - The study was multicentre (n = 3), double blind and placebo controlled. Sixty three patients who had eight or more vasospastic attacks per week were enrolled. After a one week run-in period, all patients received either iloprost or placebo treatment to a maximum tolerated dose of 150 μg twice a day for 10 days. Diary cards assessed the duration and severity of the vasospastic attacks. Side effects were monitored by direct questioning. A global assessment of treatment efficacy was made by the patient at the end of treatment and two weeks later. Results - Patient opinion tended to favour iloprost at the end of the 10 day treatment phase (p = 0.09) and this was significant at day 24 (the follow up visit) (p = 0.011). Although the duration and severity of attacks tended to decrease in the iloprost treated group, these results tended not to reach statistical significance (for severity p = 0.06 at end of treatment, p = 0.09 on day 24). Conclusion - Iloprost administered intravenously has been shown to be of benefit in the treatment of the Raynaud's syndrome associated with systemic sclerosis, but this route of administration is inconvenient. This study evaluated the use of iloprost administered orally to patients with Raynaud's syndrome. Patient documented improvement was significantly improved by iloprost. Diary card analysis showed a trend in favour of iloprost, but these results did not reach statistical significance.
Persistent Identifierhttp://hdl.handle.net/10722/53415
ISSN
2015 Impact Factor: 12.384
2015 SCImago Journal Rankings: 4.537
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorBelch, JJFen_HK
dc.contributor.authorCapell, HAen_HK
dc.contributor.authorCooke, EDen_HK
dc.contributor.authorKirby, JDTen_HK
dc.contributor.authorLau, CSen_HK
dc.contributor.authorMadhok, Ren_HK
dc.contributor.authorMurphy, Een_HK
dc.contributor.authorSteinberg, Men_HK
dc.date.accessioned2009-04-03T07:19:10Z-
dc.date.available2009-04-03T07:19:10Z-
dc.date.issued1995en_HK
dc.identifier.citationAnnals Of The Rheumatic Diseases, 1995, v. 54 n. 3, p. 197-200en_HK
dc.identifier.issn0003-4967en_HK
dc.identifier.urihttp://hdl.handle.net/10722/53415-
dc.description.abstractObjective - To compare the efficacy, tolerance and safety of 50-150 μg orally administered iloprost given twice a day versus placebo in patients with Raynaud's syndrome. Methods - The study was multicentre (n = 3), double blind and placebo controlled. Sixty three patients who had eight or more vasospastic attacks per week were enrolled. After a one week run-in period, all patients received either iloprost or placebo treatment to a maximum tolerated dose of 150 μg twice a day for 10 days. Diary cards assessed the duration and severity of the vasospastic attacks. Side effects were monitored by direct questioning. A global assessment of treatment efficacy was made by the patient at the end of treatment and two weeks later. Results - Patient opinion tended to favour iloprost at the end of the 10 day treatment phase (p = 0.09) and this was significant at day 24 (the follow up visit) (p = 0.011). Although the duration and severity of attacks tended to decrease in the iloprost treated group, these results tended not to reach statistical significance (for severity p = 0.06 at end of treatment, p = 0.09 on day 24). Conclusion - Iloprost administered intravenously has been shown to be of benefit in the treatment of the Raynaud's syndrome associated with systemic sclerosis, but this route of administration is inconvenient. This study evaluated the use of iloprost administered orally to patients with Raynaud's syndrome. Patient documented improvement was significantly improved by iloprost. Diary card analysis showed a trend in favour of iloprost, but these results did not reach statistical significance.en_HK
dc.languageengen_HK
dc.publisherB M J Publishing Group. The Journal's web site is located at http://ard.bmjjournals.com/en_HK
dc.relation.ispartofAnnals of the Rheumatic Diseasesen_HK
dc.rightsAnnals of the Rheumatic Diseases: the EULAR journal. Copyright © B M J Publishing Group.en_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshIloprost - adverse effects - therapeutic useen_HK
dc.subject.meshRaynaud Disease - drug therapy - etiologyen_HK
dc.subject.meshScleroderma, Systemic - complicationsen_HK
dc.subject.meshDouble-Blind Methoden_HK
dc.subject.meshAdministration, Oralen_HK
dc.titleOral iloprost as a treatment for Raynaud's syndrome: A double blind multicentre placebo controlled studyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0003-4967&volume=54&issue=3&spage=197&epage=200&date=1995&atitle=Oral+iloprost+as+a+treatment+for+Raynaud%27s+syndrome:+a+double+blind+multicentre+placebo+controlled+studyen_HK
dc.identifier.emailLau, CS:cslau@hku.hken_HK
dc.identifier.authorityLau, CS=rp01348en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.pmid7538285-
dc.identifier.pmcidPMC1005556en_HK
dc.identifier.scopuseid_2-s2.0-0028911625en_HK
dc.identifier.hkuros12730-
dc.identifier.volume54en_HK
dc.identifier.issue3en_HK
dc.identifier.spage197en_HK
dc.identifier.epage200en_HK
dc.identifier.isiWOS:A1995QM02900009-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridBelch, JJF=7101752870en_HK
dc.identifier.scopusauthoridCapell, HA=7005619540en_HK
dc.identifier.scopusauthoridCooke, ED=7102456986en_HK
dc.identifier.scopusauthoridKirby, JDT=7202383776en_HK
dc.identifier.scopusauthoridLau, CS=14035682100en_HK
dc.identifier.scopusauthoridMadhok, R=7102565951en_HK
dc.identifier.scopusauthoridMurphy, E=7401684017en_HK
dc.identifier.scopusauthoridSteinberg, M=7401966637en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats